segment. The time course of binding was biphasic, consisting of an initial more rapid reversible phase followed by a slower irreversible phase. The latter phase correlated with the formation of a covalent complex (Mr, 76 ,000) between 1251-Factor Xa and a vessel-localized protein presumably distinct from antithrombin III. The activation of prothrombin by vessel-bound Factor Xa was inhibited by anti-bovine Factor V IgG, suggesting that there is interaction of Factor Xa with a Factor V-like molecule provided by the endothelial cell surface. Addition of antibody to antithrombin III prevented formation of Factor Xa-antithrombin III and thrombinantithrombin III complexes in the supernatant and increased apparent thrombin activity 30-50- fold. These studies demonstrate that freshly obtained vessels with a continuous layer of native endothelium can support activation of Factor X and prothrombin: vessel-bound Factor IXa can activate Factor X in the presence of VWF/Factor VIII. Factor Xa can also bind to the vessel and participate in the activation of prothrombin. The apparent efficiency of prothrombin activation, however, is dampened by the presence of functional antithrombin III on the vessel wall.
Introduction
Localized blood coagulation is important in both hemostasis and thrombosis. Endothelial cells inhibit thrombosis by synthesis of prostacyclin (1), plasminogen activator (2) , and thrombomodulin (3) , and by the presence of antithrombin III cofactor activity (4); they have the potential to support coagulation by generation of tissue factor (5) , von Willebrand factor (VWF)' (6) , and thromboxane (7) . Recently, there has been increased interest in clot-promoting activities of endothelium, and we and other groups reported that Factors IX, IXa, X, and Xa bind to bovine aortic endothelial cells in culture (8) (9) (10) (11) (12) (13) . Cell-bound Factors IX and IXa retain their coagulant properties: cell-bound Factor IX can be activated by either the intrinsic or extrinsic pathways, and cell-bound Factor IXa can participate in Factor X activation (10) . Factor Xa incubated with nonconfluent cultured endothelial cells can activate prothrombin (14) . Conclusions from these studies rely on the assumption that cultured endothelial cells are a model for native endothelium. In the present study we have examined the interaction of Factors IX, IXa, and Xa with intact native bovine aortic endothelium to determine whether these factors could bind specifically to the surface and whether the bound factors could lead to generation of thrombin. The results of the present study indicate that the native endothelium can support the activation of Factor X and prothrombin. These reactions are influenced by the presence of antithrombin III on the vessel wall.
Methods
Coagulation factors. Bovine coagulation factors were used throughout these studies. Bovine Factor IX was purified to homogeneity (260 U/mg) by the method of Fujikawa et al. (5) . Factor IX was tritiated (3.26 X 106 cpm/Ag) as described previously (9) and its coagulant activity was unaffected by the radiolabeling procedure. Tritiated Factor IX was activated by incubation with Factor XI. bound to CNBrSepharose (Pharmacia Fine Chemicals, Piscataway, NJ) at 370C in Tris-buffered saline (0.05 M, Tris-HCI, pH 7.5, 0.1 M NaCI) containing 5 mM CaCl2 as described previously (9). A radioimmunoassay was developed to quantify the amount of Factor IX eluted from vessel segments. For the radioimmunoassay Factor IX was iodinated to achieve a higher specific radioactivity. Iodination was carried out by the lactoperoxidase method (16) using the Enzymobead Reagent (BioRad Laboratories, Sacramento, CA). After the radioiodination procedure, Factor IX retained full coagulation activity, migrated as a single chain on reduced sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with a molecular weight of 55,000, and had a specific radioactivity of 0.8-1.2 X 104 cpm/ng. Bovine Factor XI, purified to homogeneity by the method of Fujikawa et al. (17) , was activated by incubation with the Factor X activator from Russell's viper venom (18) previously coupled to CNBrSepharose in Tris-buffered saline containing 5mM CaCl2 (19) . Activation reached a plateau by 10 min as judged by coagulation assay (100 U/mg) performed by the method of Bajaj and Mann (20) , and SDS-PAGE, which showed complete cleavage of the zymogen. Active siteblocked Factor X. (Factor Xm) was prepared by reacting Factor X. in 5 mM 2-N-morpholino)-ethanesulfonic acid, pH 6.0, 0.1 M NaCl for 60 min with a 10-fold molar excess of (p-amidinophenyl)-methanesulfonyl-fluoride (Calbiochem-Behring Corp., San Diego, CA) as described HCO (pH 7.8), 175 mM NaCl, 10 mM, EDTA, 0.5 mg/ml ovalbumin; Factor Xj, active site-blocked Factor X.; FAF, fatty acid free; PAGE, polyacrylamide gel electrophoresis; S-2222, Bz-Ile-Glu-Gly-Argp-nitroanilide; S-2238, H-D-Phe-Pip-Arg-p-nitroanilide; VWF, von Willebrand factor.
by Laura et al. (21) . Unreacted inhibitor was removed by dialysis at 4VC against Tris-buffered saline. Factor Xi had no detectable activity in a clotting assay and did not hydrolyze Bz-Ile-Glu-Gly-Arg-p-nitroanilide (S2222) (Helena Laboratories, Beaumont, TX) in the Factor X. chromogenic substrate assay (see below). Factors Xa and X. were iodinated by the lactoperoxidase method as described for Factor IX.
After the iodination procedure Factor X. retained coagulant activity and had a specific radioactivity of 0.6-1.3 X 104 cpm/ng. '25I-Factor IX10 had a specific radioactivity of 0.7-1.3 X 104 cpm/ng. The radioactivity profile of reduced '251-Factor X. (Fig. 5 A) showed that the heavy chain, light chain, and activation peptide had been labeled.
Although immediately after activation Factor X. was predominantly in the a-form, by the time it was used in these studies Factor Xa was principally in the #-form (19) . '25I-Factors X. and Xm appeared identical by SDS-PAGE. SDS-PAGE of III-Factor Xa after gel filtration on Sephadex G75 in Tris-buffered saline demonstrated noncovalent association of the activation peptide with Factor X. as previously reported by Furie et al. (22) .
Bovine factor VWF/Factor VIII was prepared by the method of Newman et al. (23) . It was then chromatographed on an antifibrinogen and antifibronectin affinity column. The final material was homogenous on reduced 5% SDS-PAGE, showing one band with a molecular weight about 200,000 corresponding to the VWF. The VWF/Factor VIII preparations used in this work had a protein concentration of 1.1 mg/ml and a Factor VIII coagulant activity of 70 U/ml. Factor VIII coagulant activity in this preparation was stable over 6 mo of storage at -80°C, and no other coagulant activities (including Factors VII, IX, X, XI, and XII) were detected by clotting assay. VWF/Factor VIII (10 U/ml) was activated by incubation with bovine a-thrombin (0.01 U/ml) in Tris-buffered saline for 3 min and was used immediately (10, 24) . Bovine a-thrombin (2.5 NIH U/ag), prothrombin (13 U/mg), and Factor VII (7,100 U/mg) were purified to homogeneity as described previously (25) (26) (27) . Thrombin was iodinated by the lactoperoxidase technique (see above); the radiolabeled protein had a specific radioactivity of 4-8 X 103 cpm/ng and the coagulant activity was unaffected by radiolabeling. Factor VII, radioiodinated by the method of Fraker and Speck (28) as modified for Factor VII by Broze (29) , had a specific radioactivity of 2-4 X 103 cpm/ng and was homogeneous on SDS-PAGE, migrating as a single band of radioactivity at a molecular weight of 54,000.
Bovine antithrombin III was prepared according to Mahoney et al. (30) and was homogeneous as judged by SDS-PAGE. Radiolabeling of antithrombin III was accomplished by the lactoperoxidase method as described for Factor IX and the specific radioactivity achieved was 0.5-1.1 X 104 cpm/ng. lodinated antithrombin III comigrated with unlabeled material on SDS-PAGE.
Monospecific antisera against Factor IX, Factor VII, and antithrombin III were raised in rabbits by standard methods (31) . IgG from rabbit serum was purified by use of protein A-Sepharose CL-6B (Pharmacia Fine Chemicals) according to the manufacturer's recommendations. Burro anti-bovine Factor V IgG (32) and normal burro serum were generously provided by Drs. P. Tracy and K. Mann (Mayo Clinic, Rochester, MN). Normal burro IgG was prepared from nonimmune serum as described (31) . Purified IgG preparations had no detectable Factor XI, VII, IX, or X, or thrombin activity by clotting assay. Protein concentrations were determined colorimetrically (33) .
The concentrations of activated factors were also determined by active site titration with p-nitrophenyl-p'-guanidinobenzoate (34) . Clotting assays were done as described previously (35) and calcium concentrations were determined with murexide (36) . SDS-PAGE was carried out as described previously (9) except that samples of vessel bound '25I-Factors X. and Xj were prepared as follows: vessel segments with bound tracer were incubated for 20 min at 4VC with Tris-buffered saline containing 1% Nonidet P-40 (Sigma Chemical Co., St. Louis, MO), 10 mM EDTA, 0.5 mM phenylmethyl sulfonyl fluoride, 2 mM diisopropyl fluorophosphate. The vessel eluate was then prepared for SDS-PAGE as described previously. Electrophoresis standards included calibration proteins obtained from Pharmacia Fine Chemicals and complexes of '25I-Factor X. or '25l-thrombin with antithrombin III (37, 38) prepared by incubation of I25l-Factor Xa (5 nM) or '25l-thrombin (5 nM) with antithrombin III (10 nM) and heparin (I U/ml) in a final volume of 25 jul for 3 min.
Bovine aortas. Thoracic aortas, a generous gift of the Great American Veal Co. (Newark, NJ), were obtained from 1-yr-old calves within 5 min postmortem. Killing and exsanguination of the animals occurred simultaneously. Experiments were performed either immediately or after transport of the aortas to the laboratory (about 40 mi later). During transport, aortas were stored at 21°C immersed in Hank's balanced salt solution (Gibco Laboratories, Gibco Div., Grand Island, NY) containing 25 mg/ml bovine serum albumin, fatty acid free (BSA-FAF). For binding and activation studies the surrounding fat was removed and aortas were cut longitudinally between the intercostal vessels into 4.5 X 21 cm segments, spread flat, and placed within a Lucite template. The Lucite template consisted of two sheets of half-inch-thick Lucite. The lower sheet was solid, and the upper sheet was prepared by drilling 0.79, 3.8, or 10 cm2 holes at regular intervals. Aortic segments were placed on the lower sheet and covered with the upper sheet. The sheets fit closely together so that wells were formed by the holes in the upper sheet. These wells did not leak during the incubation period and >98% of the added counts could be recovered. Control experiments were carried out in natural depressions in the vessel formed by resting the aorta on top of the upper sheet of the Lucite template; natural depressions of roughly the same volume as those generated by the 3.8 cm2 well area were selected. Other experiments were performed directly on lucite sheets without aortas to exclude possible artifacts due to lucite-coagulation factor interaction. Some aortas were treated with collagenase (0.1%, CLSII; Worthington Biochemical Corp., Freehold, NJ) in Dulbecco's phosphate buffered saline by incubating the luminal surface of the vessel with the enzyme preparation for 10 min at 37°C. Soybean trypsin inhibitor (0.5 mg/ml; Sigma Chemical Co.) was added for 5 min at 21°C to neutralize tryptic activity in the collagenese preparation, and aortas were washed extensively with 10 ml of buffer A (10 Morphological study of the vessels was carried out by scanning electron microscopy using standard procedures (39) .
Binding and activation studies on aortic segments. Binding studies were carried out at 21 'C. After the aorta was opened and placed beneath the template, each well was washed five times with buffer A without calcium, incubated with buffer B for 30 s, and finally washed twice with buffer A in order to remove plasma and Factor IX bound in vivo from the endothelium. The integrity of the endothelium was assessed microscopically (see below). Next, I ml buffer A was added to each 3.8 cm2 well, and 0. '25I-Factor X. and the vessel was washed free of unbound ligand, buffer A (0.5 ml/well) was added. At the specified times, buffer A was removed, the wells were washed, and more buffer A (0.5 ml) was added. Then the wells were washed with buffer A again and the cells solubilized as described above. Activation studies were carried out at 21 'C in wells (0.79 cm2) prepared with buffers A and B as for binding studies. To study activation of Factor X and prothrombin by Factors IX. and VWF/Factor VIII, 3H-Factor IXa (1-5 nM) and VWF/Factor VIII (2 U/ml) in 0.5 ml of buffer A were equilibrated with the aorta for 30 min. The wells were then washed five times with buffer A (0.5 ml/wash) and finally filled with 0.5 ml of buffer A. Factor X (0.21 AM) with or without prothrombin (1.4 AM) was then added to the well. Thrombin (0.1 nM) was added to effect rapid activation of VWF/ Factor VIII. When prothrombin activation by Factor X. was studied, wells were incubated with 125I-Factor X. (3-60 nM) , washed, and then prothrombin (1.4 MM) was added. In the experiments using antibodies, either nonimmune burro or rabbit IgG, or anti-Factor V IgG or antiantithrombin III IgG was added to 0.5 ml of buffer A and equilibrated with the aortic wells for 40 min at 21 'C before the addition of clotting proteins. Samples for Factor X. and thrombin assay were obtained by the addition of 0.5 ml buffer C (50 mM Tris-HCl [pH 7.8], 175 mM NaCl, 10 mM EDTA, 0.5 mg/ml ovalbumin) to each well and then withdrawing 0.2 ml for assay. Where specified, 0.1-ml aliquots were withdrawn from reaction wells and placed in glass tubes. Buffer C (0.2 ml) was then added either immediately or after 10-20 min. Samples were assayed for Factor X. by monitoring hydrolysis of the chromogenic peptide, S-2222 (24). Thrombin was assayed (41) by the same protocol as for Factor X., with H-D-Phe-Pip-Arg-p-nitroanilide (S-2238) (Helena Laboratories) at 0.1 mM final concentration. Factor X. inactivation studies were carried out with the S2222 assay by the method of Odegard et al. (42) . Control wells incubated with 0.1 nM of thrombin (as used for activation of VWF/Factor VIII) or with buffer alone showed no significant hydrolysis of either synthetic substrate under these conditions. The amounts of Factor X, and thrombin formed were determined from the linear portion of a standard curve in which known amounts ofFactor X, or thrombin were assayed under conditions identical to the experimental samples. Although qualitatively the results were similar in each binding and activation experiment and yielded similar dose-response relationships, the base line varied by as much as two-to threefold from one experiment to another. Accordingly, the figures present results from representative experiments.
Radioimmunoassays for Factor IX, Factor VII, and antithrombin III. Radioimmunoassay for Factor IX antigen was carried out using a specific rabbit antiserum for bovine Factor IX generously provided by Dr. K. Fujikawa (University of Washington, Seattle, WA). The assay was carried out by the method of Suzuki and Thompson (43) . The limit of detection in this assay was 1.1 nM Factor IX antigen, which corresponded to 80% binding on the standard curve. This assay did not distinguish between Factor IX and Factor IX,. The assay for Factor VII was carried out by the same protocol described for Factor IX, using a monospecific rabbit anti-bovine Factor VII antiserum.
The limit of detection was 2 nM. The assay for antithrombin III using a monospecific rabbit antibody was also carried out by the same protocol except that all tubes (including the standards) had a final concentration of 0.5% Nonidet P-40. The limit of detection in this assay was I nM.
Results
Microscopic study of calf aortas. A continuous layer of endothelium was present on the vessels at the end of the incubation period (data not shown). Examination by scanning electron microscopy showed no evidence of cytoplasmic rupture, endothelial loss, exposure of the internal elastic laminae, or adherent platelets. The cells did, however, appear protuberant as a result of a lack of transmural pressure. Direct cell counts showed 1±0.04 X 106 cells/cm2 (mean± 1 SD) vessel surface area. Aortas treated with collagenase showed total loss of endothelium.
Factor IX/IXa studies Binding. Elution of Factor IX from bovine aortic segments was studied to assess binding of endogenous Factor IX at the time of slaughter. Eluates obtained from aortas 5 min postmortem were tested for Factor IX antigen by radioimmunoassay (Table I) . A small amount of Factor IX antigen was observed 16-19% of the total binding (0.4-0.5% of the added tracer). Activation. Vessel-bound 3H-Factor IXa in the presence of VWF/Factor VIII activated added Factor X (Fig. 1 A) . If unactivated VWF/Factor VIII was added in place of the thrombin-treated VWF/Factor VIII, Factor X activation occurred though there was a slightly longer lag (2-3 min with unactivated Factor VIII as compared with 1-1.5 min with activated Factor VIII) before Factor Xa activity was detected. When prothrombin was added along with Factors VIII and X, vessel-bound 3H-Factor IX. initiated a series of reactions leading to thrombin formation (Fig. 1 C) . Unlabeled Factor IXa promoted activation of Factor X and prothrombin under the same conditions. Interaction of coagulation factors with the endothelium was essential for Factor X. and thrombin formation, as no activation was observed when the proteins were mixed on a Lucite plate in the absence of an aortic segment or when collagenase-treated vessel segments devoid of endothelium replaced the intact segments. Furthermore, when an aliquot of the reaction mixture was removed from the reaction well and incubated in a glass tube, no additional activation of Factor X or prothrombin occurred. The amount of Factor X. formed in 10 min was correlated with the amount of 3H-Factor IXa specifically bound to the aorta (Fig. 1 A) .
Omission of Factor IX., VWF/Factor VIII substitution of Factor IX for Factor IX,, or elution of specifically bound 3H-Factor IX. with calcium-free buffer prevented Factor X. formation on bound Factor IXa. 3H-Factor IX, (1-5 nM) and VWF/ Factor VIII (2 U/ml), 10 Al each, were added to wells containing 0.5 ml buffer A and incubated for 10 min. After aspiration and washing, 0.5 ml buffer A and 10 ,ul each of thrombin (0.1 nM) and Factor X (0.21 ,uM) were added and followed by a 10-min incubation. Then 0.5 ml buffer C was added to each well, and a 0.2-ml aliquot of the supernatant was removed for the S-2222 synthetic substrate assay. formation. In addition, the inclusion of a 500-fold molar excess of Factor IX in each initial incubation mixture in Fig.  1 A blocked Factor X activation and specific 3H-Factor IX, binding by >90%. The amount of Factor X. formed could also be correlated with the concentration of exogenous VWF/ Factor VIII ( Fig. 1 B) added. The retention of Factor VIII activity on the aorta after washing of the vessel suggests that Factor VIII bound to the vessel wall. Thrombin formation initiated by cell-bound 3H-Factor IX. occurred only in presence of VWF/Factors VIII, X, and prothrombin and correlated well with the amount of specifically bound 3H-Factor IX. (Fig. C) .
Factor Xa studies Binding. Incubation of '25I-Factor X. with bovine aortic segments resulted in progressive loss of Factor X. activity in the supernatant (Fig. 2 A) . When aliquots of the incubation mixture were removed at various times and analyzed by SDS-PAGE, the radioactivity profile showed formation of a new slowly migrating peak (labeled X6-ATIII in Fig. 2, B and C) . After a 1-min incubation of Factor XN with the vessel segment (Fig. 2   B) , 49% of the initial Factor X. activity was lost and 46% of the added Factor X, was present in the higher molecular weight peak. After a 28-min incubation of '25I-Factor X. with the vessel segment (Fig. 2 C) , 94% of the initial Factor Xa activity was lost and 90% of the added Factor X. was present in the peak labeled X6-ATIII. This high molecular weight peak varying amounts of VWF/Factor VIII (0.15-17 U/ml) each in a volume of 15 Ml were added to 0.5 ml of buffer A in 0.79 cm2 wells and incubated for 10 min at 21 'C. After aspiration and washing, Factor X and thrombin were added and the procedure was carried out as in A. (C) Activation of prothrombin. Aortic segments were incubated with 3H-Factor IX. and VWF/Factor VIII (2 U/ml), then washed as described above. Next, 10 Ml of prothrombin (1.4 MM) was added along with Factor X and thrombin (0.1 nM). The remainder of the procedure was identical to that described in A except that S-2238 was used in the synthetic substrate assay. The amount'of specifically bound 3H-Factor IX. is plotted against thrombin formed.
In A-C above each point is the mean of duplicate wells from a single representative experiment. The experiments were repeated four times and in each case not more than 3% of the available substrate was activated.
represented '251-Factor X. complexed with antithrombin III since it comigrated with the 1251I-Factor Xc-antithrombin III standard and its formation could be blocked by >90% when vessel segments were pre-incubated with anti-antithrombin III IgG (600 ug/ml). Since no antithrombin III was added to these incubation mixtures, it seemed possible that the source of this protein was vessel-associated antithrombin III. To confirm this, vessel segments were washed with buffer A until no further antithrombin III antigen could be detected and then eluted with Tris-buffered saline containing 1% Nonidet P40. The amount of antithrombin III antigen eluted from the vessel wall corresponded to 3.8±0.5 pmol/106 cells (Table I) .
Association of '251-Factor X. with the vessel was then examined. 1251I-Factor X. bound in a time-dependent manner to the vessel segment, and the amount of specifically bound 1251-Factor Xa (Fig. 3) inactivation was assessed by chromogenic substrate assay at the indicated times (see text). In B and C, aliquots of supernatant were subjected to nonreduced 7.5% SDS-PAGE. The incubation times were I and 28 min in B and C, respectively. Labeled peaks correspond to Factor X,-antithrombin III complex (X.-AT III), Factor X., and activation peptide (AP).
and was not affected by the presence of the antithrombin III antibody or addition of exogenous antithrombin III. In addition, when vessel segments were pre-incubated with thrombin, binding of '25I-Factor Xa (Fig. 3) Comparison of the vessel binding of 251I-Factors X. and X5j (Fig. 4 A) showed that the time course of '251I-Factor X. (1 nM) binding appeared biphasic, consisting of a more rapid initial phase which was complete within 3-4 min and a steadily increasing slower component. The initial phase of '251I-Factor Xdi binding was identical to Factor X. binding. However, in contrast to '25I-Factor X., the binding of 125I-Factor Xj (1 nM) reached an apparent maximum after 4 min and did not change later. Binding of 251I-Factor X., which was allowed to proceed for only 3 min, was largely reversible (Fig. 4 A) binding to bovine aortic segments. Aortas (0.79 cm2 wells) were preof specifically bound '251I-Factors X. and Xa1 (Fig. 4 B) (Fig. 5) . At 2 min of incubation (Fig. 5 B) , when the 125I-Factor X, was mainly bound reversibly, the radioactivity profile is similar to that of the initial tracer (Fig. 5 A) . However, after longer incubation (Fig. 5 C) , the radioactivity profile of bound '25I-Factor Xe,, but not of 1251. Factor X.. (Fig. 5 D) , showed a new slowly migrating peak with a molecular weight of 76,000 on unreduced (V, Fig. 5 C) incubated with anti-antithrombin III IgG (600 ,ug/ml) for 40 and 63,000 on reduced (V) SDS-PAGE. The vessel-bound complex had a different molecular weight on unreduced SDS-PAGE (76,000) than did the Factor X.-antithrombin III complex found in the supernatant (84,000) (Fig. 2) . Also, formation of the vessel bound complex was not blocked by anti-antithrombin III IgG. 251I-Factor X.-vessel wall complexes, solubilized in Nonidet P-40 (1%) could not be immunoprecipitated with anti-antithrombin III IgG under conditions that immunoprecipitated Factor X.-antithrombin III complexes.
Reversibility studies (Fig. 4 A) showed that the same amount of '251I-Factor X. dissociated at 3 min of incubation, when no covalent Factor Xe-vessel wall complex (Mr 76,000) had formed, and at 18 min of incubation, when the latter complex had formed. The amount of nondissociable bound 1251-Factor X.
increased from 3 to 18 min of incubation in parallel with formation of the Mr 76,000 complex. Unreduced SDS-PAGE showed that the radioactivity profile of the dissociated 125I1 Factor X., in the presence of anti-antithrombin III IgG (500 yg/ml), was identical to that of the initial tracer. Factor X. in the 76,000 mol wt complex remained vessel associated (data not shown). The '25I-Factor X,-vessel wall complex (Mr 76,000) thus accounts for the steadily increasing phase of irreversible binding.
Competitive binding studies carried out in the presence of antibody to antithrombin III (Fig. 6) showed no significant inhibition of 1251-Factor X. binding by Factors were also carried out with a 4-min incubation, when >90% of the Factor X. was reversibly bound, and at 90 min, when -80% of the Factor X. was in the Mr 76,000 complex. In each case, the other cogulation proteins did not inhibit 251I-Factor Xe-vessel wall binding. Binding of 125I-Factor X, was calcium dependent, maximal at 3 mM Ca++, and decreased by 20-30% from 3 to 10 mM Ca++.
Activation. Prothrombin activation studies were performed on aortic segments to assess the coagulant activity of bound '25I-Factor X,. Vessel-bound '25I-Factor Xa activated added prothrombin as measured by increasing levels of amidolytic activity in the S2238 assay (Fig. 7) . Thrombin formation depended upon the presence of Factors X. and prothrombin, as well as on the binding of '25I-Factor X. to the endothelium, since no activation of prothrombin by Factor X, was observed on aortic segments previously treated with collagenase. Furthermore, when aliquots of the reaction mixture supernatant were withdrawn from contact with the endothelium at intervals and incubated in a test tube, no further thrombin formation occurred. The amount of thrombin formed on aortic segments was correlated with the amount of bound '251-Factor Xa (Fig.   7 ) and depended upon the interaction of Factor X. with an endothelial cell Factor V-like molecule, as shown by 75-90% inhibition of prothrombin activation in the presence of antiFactor V IgG (Fig. 7) , though this concentration of antibody blocked '251I-Factor X. binding by only 10-30% (data not shown). The effect of anti-antithrombin III IgG on the activation of prothrombin by vessel-bound '25I-Factor X. was studied by comparing the amount of thrombin generation in the supernatant of wells incubated with anti-antithrombin III IgG or nonimmune IgG (Fig. 8) . In the presence of antiantithrombin III IgG (600 ,tg/ml), formation of Factor X.-antithrombin III complex was inhibited by 90-95% and formation ofthrombin-antithrombin III complex was inhibited by -70% as judged by SDS-PAGE of reaction mixtures. Wells pre-ihcubated with anti-antithrombin III IgG (Fig. 8 A) showed 30-50-fold more thrombin activity in the supernatant. The apparent increase in thrombin activity correlated well with the dose of anti-antithrombin III IgG and reached a plateau at 500-800 sug/ml of added antibody (Fig. 8 B) . In this range of antibody concentration, complex formation between antithrombin III and the two proteases was not blocked further by addition of more IgG (data not shown).
Discussion
These studies were initiated to examine the interaction of bovine Factors IX, IX,, and Xa with a continuous layer of native endothelium. Previously it has been reported that Factors IX, IX,, and X, bind to cultured bovine aortic endothelial cells (8) (9) (10) (11) (12) (13) . Bound Factor IX. can activate Factor X in the presence of VWF/Factor VIII (10) and Factor Xa can activate prothrombin when the cultured cells are subconfluent (14) . Factor V synthesis by cultured endothelial cells has also been reported (44) . Since endothelial cells are generally considered to inhibit hemostasis and thrombosis, we have investigated whether these clot-promoting phenomena observed with cultured cells can also be found with native endothelial cells. In an in vivo system, Factor X. binding to mouse aortas has been observed (45) . In our studies the source of native endothelium was calf aortas because of the relative ease of obtaining and handling aortic tissue.
The presence of Factor IX antigen in the EDTA-eluates from vessels harvested immediately after slaughter ( '251I-Factor X. (5 jil; 3-30 nM) was then added to the wells and incubated for 5 min. Unbound '251-Factor X. was removed by washing with buffer A, and 0.5 ml of buffer A containing either antiFactor V IgG or control IgG was added to each well. The same IgG as for the initial incubation followed by 7.5 Ml of prothrombin (1.4 MM) was then added. Reaction mixtures were incubated for 10 min and terminated by the addition of 0.5 ml buffer C, and 0.2-ml aliquots were assayed for thrombin activity as described in Methods. Specific '25I-Factor X. binding was determined as described in Fig. 3 .
Thrombin concentration at 10 min is plotted against the amount of specifically bound 1251I-Factor Xa. The mean of duplicate measurements is shown, and the experiment was repeated three times.
be associated with perturbation ofthe endothelium, and infusion studies may provide further insight into the binding of Factor IX to the vessel wall in vivo. Factor VII, a coagulation factor reported not to bind specifically to bovine aortic endothelial cells in culture (46) , was selected as a control for the vessel wall elution studies of Factor IX (Table I) .
Factor IX. bound to vessel segments activated Factor X in the presence of exogenous VWF/Factor VIII and in the absence of exogenous phospholipid (Fig. 1, A and B) . In the experiments shown in Fig. 1 III dissociates first and then Factor Xa-antithrombin III complex formation occurs in the supernatant), but the antithrombin III is clearly associated with the vessel at the start of the experiment (Table I ). The mechanism responsible for this localization of antithrombin III to the vessel is currently under study. One possibility is that plasma antithrombin III binds to the vessel in vivo (50) . Alternatively, constitutive synthesis of antithrombin III by endothelium, which has been reported for cultured human umbilical vein endothelial cells (51), may be involved.
Incubation of Factor Xa with calf aortic segments showed the presence of time-dependent, specific binding (Fig. 3) . The presence of antithrombin III decreased Factor Xa-vessel wall binding, whereas addition of anti-antithrombin III IgG, which blocked formation of "25I-Factor Xe-antithrombin III complex (Fig. 2, B and C) , promoted binding. This suggested that '25I-Factor Xe, complexed with antithrombin III, no longer binds to the vessel segments. This suggestion was confirmed by experiments in which 125I-Factor Xa, pre-incubated with a twofold molar excess of antithrombin for 60 min at 370C, did not subsequently bind specifically to the vessels (unpublished observation). Also, SDS-PAGE of vessel-bound '25I-Factor Xa did not reveal the presence of '25I-Factor Xa-antithrombin III complex (Fig. 5, B and C) . Binding of 125I-Factor Xa to aortas in the presence of the plasma concentration of antithrombin III suggested that Factor Xa binding to the vessel wall may occur physiologically. This observation led us to investigate further Factor Xe-vessel wall interaction. Time-dependent binding of Factor Xa to aortic segments (Fig. 4) was biphasic, with an initial rapid, largely reversible phase and a subsequent irreversible phase. Reversible binding was similar for '251I-Factor Xe and 125I-Factor Xa, (Fig. 4) , suggesting that integrity of the active site was not necessary for this vessel wall interaction. In contrast, the slower irreversible phase ofbinding required the active site and was due to formation of a covalent complex between Factor Xa and a vessel-associated protein (Fig. 5) . Factor Xa bound to this site remained on the surface of the vessel since brief trypsin treatment (2 mg/ml trypsin for 4 min at 21 'C) did not remove the endothelium but did result in rapid dissociation of bound radioactivity. The nature of this '25I-Factor Xe vessel wall complex is unclear, though it appears to differ in its molecular weight and antigenic characteristics from Factor Xe-antithrombin III complex. Competitive binding studies (Fig. 6) (14) . These differences might be due to the variety of methods used to inactivate Factor Xe or to different sources of endothelium, i.e., cultured vs. native endothelium.
Factor Xe bound to aortic segments activated prothrombin (Fig. 7) , though only small amounts ofthrombin were detectable in the supernatant. Studies with anti-antithrombin III IgG (Fig. 8) suggested that most of the Factor Xe added and thrombin formed were inactivated by antithrombin III initially associated with the surface of the vessel. Thus, in the presence of anti-antithrombin III IgG, which prevented antithrombin III protease complex formation, the amount of bound '25I-Factor Xe (Fig. 3 ) and the amount of detectable thrombin in the amidolytic S2238 assay increased. The actual amount of thrombin formed per mole of Factor Xe bound may have been unchanged. Under conditions of compromised blood flow in which exposure ofthe vessel wall to plasma antithrombin III might be reduced and/or antithrombin III associated with the vessel might dissociate, it is possible that more of the Factor Xe and thrombin formed may remain active, potentially leading to fibrinogen cleavage and clot formation.
The presence of antithrombin III on the vessel surface is one mechanism by which the vessel wall is protected from activation of the coagulation system. Another potential protective mechanism is competition by Factors IX and IXe for the same cellular binding site. When small amounts of Factor IXe are formed in the supernatant, no Factor IXa binding will occur as long as there is continuous blood flow to ensure a large excess of the zymogen, Factor IX. However, when the amount of Factor IXa in the supernatant increases, Factor IXa binding could occur, as Factor IX already bound to the endothelium dissociates. (50% of bound Factors IX/IXa dissociates in 30 min at 4VC (9) and in 10 min at 230C.) Alternatively, activation of cell-bound Factor IX would lead to Factor IXa localized to the vessel wall. This cell-bound Factor IXa could then participate in Factor X activation since the dissociation of Factor IXa from its cellular binding site is slow. We have previously demonstrated activation of Factor IX bound to quiescent endothelial cells by Factor XIa and activation of Factor IX bound to endotoxin-treated endothelial cells, which express tissue factor, by Factor VIIa (10). The cellbound Factor IXa formed did activate Factor X in the presence of VWF/Factor VIII. Therefore, an endothelial cell-dependent pathway of coagulation, initiated by perturbed endothelial cells expressing tissue factor and culminating in thrombin formation, may be an important mechanism for activation of the coagulation system in localized areas of vessel wall pathology. In these areas Factor IXa could be formed on the surface of endothelial cells, and Factor X and prothrombin activation could proceed rapidly when the amount of antithrombin III on the vessel wall is decreased.
